Document Detail


Long-term patient benefit with biodegradable polymer biolimus eluting stent.
MedLine Citation:
PMID:  23147439     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The introduction of bare metal stents in the early 1990 and of 1st generation drug eluting stents (DES) in the early 2000 defined a new era in interventional cardiology. DES dramatically reduced instent restenosis and the need of revascularization after percutaneous coronary intervention. However, this increased efficacy came at the cost of delayed vascular healing and subsequent late adverse event such as late stent thrombosis. Second generation DES appears even more efficient and safer than 1st generation DES, providing exciting perspectives for the near future. A new era has started with the development of bio-absorbable polymers. Biodegradable polymer eluting stents, such as the biolimus A9 eluting stent showed non-inferiority to durable polymer sirolimus eluting stent and, by reducing the risk of cardiac events associated with very late stent thrombosis, might improve long-term clinical outcomes in a variety of patients including chronic stable coronary artery disease and acute coronary syndromes. Biodegradable polymer DES are more likely to define the 3rd generation DES. The goal of future development is to further increase safety and efficacy of DES.
Authors:
R Corti
Related Documents :
15249499 - Association of anti-heat shock protein 65 antibodies with development of postoperative ...
20869199 - Risk of cardiac arrhythmias and conduction abnormalities in patients with acute myocard...
15474699 - Impairment of left atrial function predicts post-operative atrial fibrillation after co...
1382889 - Postextrasystolic potentiation and its contribution to the beat-to-beat variation of th...
14723019 - Rhythm-independent feature of heart rate dynamics common to atrial fibrillation and sin...
16321669 - Prediction of atrial fibrillation after coronary artery bypass grafting: the role of ch...
22319069 - Clinical outcomes and treatment after drug-eluting stent failure: the absence of tradit...
11029719 - Echocardiographic assessment of stentless aortic bioprosthetic valves.
10577569 - Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 g...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  60     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  629-36     Citation Subset:  IM    
Affiliation:
Andreas Grüntzig Laboratories Cardiology, University Hospital Zurich, Zurich, Switzerland - roberto.corti@usz.ch.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dual antiplatelet therapy for primary and secondary prevention.
Next Document:  Ventricular tachycardia in "end stage" hypertrophic cardiomyopathy: a role of dronedarone.